Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Status:
Completed
Trial end date:
2019-08-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of sorafenib for prophylaxis of
leukemia relapse in allogeneic stem cell transplant (Allo-HSCT) recipients with FLT3-ITD
positive acute myeloid leukemia (AML).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First People's Hospital of Chenzhou Fujian Medical University Guangdong General Hospital Guangzhou First Municipal People’s Hospital Guangzhou General Hospital of Guangzhou Military Peking University People's Hospital Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Affiliated Hospital of Guangzhou Medical University Third Affiliated Hospital, Sun Yat-Sen University Xiangya Hospital of Central South University Zhujiang Hospital